Delivery Order SPE2DB20D1102-SPE2DB25FC6VY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $3,061.96 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 micrograms capsules (30-count units) on September 9, 2025, with completion targeted for September 10, 2025. This firm fixed price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award supports the company's...
- The Defense Logistics Agency awarded a $3,410.04 delivery order to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count unit of use packaging) with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with the...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Linzess 145 mcg capsules (quantity: 30 units) with a ceiling value of $1,982.96. This is a firm fixed price delivery order with an award date of September 10, 2025, and an ultimate completion date of September 11, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units) valued at $9,140.32. This is a firm fixed-price, competitive delivery order with no set-aside designation and an ultimate completion date of September 15, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a $1,678.18 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 microgram capsules (30-count units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the awardee's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB20D1102Indefinite Delivery Contract
- SPE2DB20D1102-SPE2DB25FC6VYDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.40 to AmerisourceBergen Drug Corp for Linzess 145 microgram capsules (30-count units) under a firm fixed-price contract. The award was made on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside contract represents a competitive award to the prime contractor, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of medications, vaccines, medical devices, and healthcare commodities to support military and veteran healthcare systems. The Linzess procurement reflects the company's role in fulfilling specialized pharmaceutical needs across the Defense Health Agency and other federal healthcare systems, with the product providing gastrointestinal therapeutic support for eligible military beneficiaries and federal patients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/16/25 |